Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Soyza, Anthony De
CLEAR, NCT04140214 / 2017-000664-14: Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis	Completed	3	288	Europe	Hypertonic saline, MucoClear 6%, HTS, Carbocysteine 750 MG, Mucodyne	Belfast Health and Social Care Trust, Queen's University, Belfast	Bronchiectasis	09/24	12/24
Strong, Amy
REFINE, NCT04913025 / 2006-004858-25: REduced Frequency ImmuNE Checkpoint Inhibition in Cancers	Recruiting	2	160	Europe	Nivolumab, Pembrolizumab	University College, London, JP Moulton Charitable Foundation	Renal Cell Carcinoma, Melanoma	04/25	04/25
ADAPT-P, NCT06019676: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients	Recruiting	N/A	170	Europe		Royal Marsden NHS Foundation Trust, Janssen, LP	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	04/27	04/27
Pearson, Rachel
PACE-NODES, NCT05613023: A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT	Recruiting	3	1128	Europe, RoW	SBRT, SABR	Institute of Cancer Research, United Kingdom, Prostate Cancer UK	Prostate Cancer	06/28	06/30
iPREDICT, NCT05013099 / 2021-005610-33: Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies	Active, not recruiting	2	70	Europe, US, RoW	zirconium Zr 89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C	ImaginAb, Inc.	Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma, Non Small Cell Lung Cancer	07/25	07/25
ADAPT-P, NCT06019676: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients	Recruiting	N/A	170	Europe		Royal Marsden NHS Foundation Trust, Janssen, LP	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	04/27	04/27
Robertson, Stuart
ADAPT-P, NCT06019676: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients	Recruiting	N/A	170	Europe		Royal Marsden NHS Foundation Trust, Janssen, LP	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	04/27	04/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Soyza, Anthony De
CLEAR, NCT04140214 / 2017-000664-14: Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis	Completed	3	288	Europe	Hypertonic saline, MucoClear 6%, HTS, Carbocysteine 750 MG, Mucodyne	Belfast Health and Social Care Trust, Queen's University, Belfast	Bronchiectasis	09/24	12/24
Strong, Amy
REFINE, NCT04913025 / 2006-004858-25: REduced Frequency ImmuNE Checkpoint Inhibition in Cancers	Recruiting	2	160	Europe	Nivolumab, Pembrolizumab	University College, London, JP Moulton Charitable Foundation	Renal Cell Carcinoma, Melanoma	04/25	04/25
ADAPT-P, NCT06019676: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients	Recruiting	N/A	170	Europe		Royal Marsden NHS Foundation Trust, Janssen, LP	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	04/27	04/27
Pearson, Rachel
PACE-NODES, NCT05613023: A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT	Recruiting	3	1128	Europe, RoW	SBRT, SABR	Institute of Cancer Research, United Kingdom, Prostate Cancer UK	Prostate Cancer	06/28	06/30
iPREDICT, NCT05013099 / 2021-005610-33: Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies	Active, not recruiting	2	70	Europe, US, RoW	zirconium Zr 89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C	ImaginAb, Inc.	Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma, Non Small Cell Lung Cancer	07/25	07/25
ADAPT-P, NCT06019676: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients	Recruiting	N/A	170	Europe		Royal Marsden NHS Foundation Trust, Janssen, LP	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	04/27	04/27
Robertson, Stuart
ADAPT-P, NCT06019676: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients	Recruiting	N/A	170	Europe		Royal Marsden NHS Foundation Trust, Janssen, LP	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	04/27	04/27